{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T11:19:19Z","timestamp":1774005559530,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["CA204786"],"award-info":[{"award-number":["CA204786"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA292333"],"award-info":[{"award-number":["R21CA292333"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.isci.2025.114552","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T16:05:29Z","timestamp":1766765129000},"page":"114552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined prostate cancer vaccine plus immune checkpoint inhibition synergizes to eliminate prostate cancer"],"prefix":"10.1016","volume":"29","author":[{"given":"Gabriel","family":"Carreno-Galeano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth A.","family":"Iczkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Van Veldhuizen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uzoma A.","family":"Anele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie C.","family":"Messer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murali K.","family":"Ankem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0905-0886","authenticated-orcid":false,"given":"Dev","family":"Karan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2025.114552_bib1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.114552_bib2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","article-title":"Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population","volume":"27","author":"Freedland","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.isci.2025.114552_bib3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/pros.24850","article-title":"Time to Castration Resistance is Associated With Overall Survival Even After the Achievement of Castration Resistance in Metastatic Prostate Cancer","volume":"85","author":"Kato","year":"2025","journal-title":"Prostate"},{"key":"10.1016\/j.isci.2025.114552_bib4","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114552_bib5","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114552_bib6","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","article-title":"How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer","volume":"24","author":"Stultz","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.isci.2025.114552_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104576","article-title":"Advancing tumor vaccines: Overcoming TME challenges, delivery strategies, and biomaterial-based vaccine for enhanced immunotherapy","volume":"205","author":"Zeng","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.isci.2025.114552_bib8","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3389\/fphar.2019.01184","article-title":"Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment","volume":"10","author":"Zhao","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2025.114552_bib9","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1016\/j.vaccine.2017.09.037","article-title":"Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice","volume":"35","author":"Karan","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.isci.2025.114552_bib10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2217\/imt.11.59","article-title":"Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice","volume":"3","author":"Karan","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.isci.2025.114552_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194757","article-title":"Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances","volume":"13","author":"Movassaghi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2025.114552_bib12","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114552_bib13","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.2217\/fon-2022-0776","article-title":"KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer","volume":"18","author":"Gratzke","year":"2023","journal-title":"Future Oncol."},{"key":"10.1016\/j.isci.2025.114552_bib14","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.2217\/fon-2020-1133","article-title":"KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer","volume":"17","author":"Petrylak","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.isci.2025.114552_bib15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.euo.2024.05.013","article-title":"Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D","volume":"8","author":"Yu","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.isci.2025.114552_bib16","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1158\/1078-0432.CCR-06-2318","article-title":"A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114552_bib17","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.isci.2025.114552_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114552_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1344272","article-title":"Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors","volume":"15","author":"Ouyang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.114552_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-024-01628-4","article-title":"Personalized nanovaccines for treating solid cancer metastases","volume":"17","author":"Feng","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2025.114552_bib21","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114552_bib22","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114552_bib23","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jconrel.2024.10.057","article-title":"Extracellular vesicles powered cancer immunotherapy: Targeted delivery of adenovirus-based cancer vaccine in humanized melanoma model","volume":"376","author":"Mathlouthi","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.isci.2025.114552_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1350208","article-title":"Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy","volume":"15","author":"Shebbo","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.114552_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94573-y","article-title":"A new insight into aggregation of oncolytic adenovirus Ad5-delta-24-RGD during CsCl gradient ultracentrifugation","volume":"11","author":"Stepanenko","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.114552_bib26","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1158\/1078-0432.CCR-09-1910","article-title":"Phase I clinical trial of an adenovirus\/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results","volume":"15","author":"Lubaroff","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114552_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002374","article-title":"Phase I study of a multitargeted recombinant Ad5 PSA\/MUC-1\/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Bilusic","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2025.114552_bib28","article-title":"What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models)","volume":"22","author":"Palicelli","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.114552_bib29","first-page":"7","article-title":"Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway","volume":"6","author":"Lee","year":"2015","journal-title":"For. Immunopathol. Dis. Therap."},{"key":"10.1016\/j.isci.2025.114552_bib30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2025.114552_bib31","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s13311-018-0650-3","article-title":"A Dendritic Cell-Targeted Adenoviral Vector Facilitates Adaptive Immune Response Against Human Glioma Antigen (CMV-IE) and Prolongs Survival in a Human Glioma Tumor Model","volume":"15","author":"Kim","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.isci.2025.114552_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00262-008-0533-2","article-title":"Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus","volume":"58","author":"Vujanovic","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.isci.2025.114552_bib33","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4049\/jimmunol.177.2.1052","article-title":"CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism","volume":"177","author":"Engelhardt","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2025.114552_bib34","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.4049\/jimmunol.177.7.4376","article-title":"Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo","volume":"177","author":"Read","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2025.114552_bib35","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.omto.2021.11.014","article-title":"Current development in adenoviral vectors for cancer immunotherapy","volume":"23","author":"Biegert","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.isci.2025.114552_bib36","first-page":"5260","article-title":"Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection","volume":"62","author":"Miller","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2025.114552_bib37","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/ijc.22873","article-title":"Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine","volume":"121","author":"Karan","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.isci.2025.114552_bib38","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat. Commun."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225028135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225028135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T09:13:38Z","timestamp":1773998018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004225028135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2589004225028135"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2025.114552","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined prostate cancer vaccine plus immune checkpoint inhibition synergizes to eliminate prostate cancer","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2025.114552","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114552"}}